Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the health and performance outcomes associated with supplementation of Veillonella atypica.


Clinical Trial Description

This pilot study will be conducted using a randomized, double-blind, crossover study design. Healthy men and women (n=7) between the ages of 18 - 50 years of age will be recruited for this study. After signing an IRB-approved consent form, participants will have their peak VO2 determined to finalize eligibility. Eligible participants will then practice their first time to exhaustion trial at 100% VO2Peak. Prior to each subsequent study visit, participants will be scheduled at a similar time between the hours of 0600 and 1000 hours and will be asked to observe an overnight fast (food, caffeine, and nicotine) while refraining from any vigorous exercise for at least 24 hours prior to their visit. During visit 2, participants will have their body composition assessed and complete another time to exhaustion familiarization at 100% VO2Peak. Leading up to and during each subsequent study visit (identical to visit 3), participants will collect a stool sample and upon arrival at the laboratory have their body mass measured before having a venous blood sample collected for assessment of complete blood count and comprehensive metabolic panel. After blood collection, participants will complete the standardized warm-up before completing a treadmill time to exhaustion test at 100% VO2Peak. Capillary lactate levels will be assessed before, immediately after, and 5 minutes after completion of the exhaustion trial using a handheld lactate analyzer. From there and in a randomized, double-blind, placebo-controlled, crossover fashion, participants will be assigned for the next 14 days to ingest either a placebo (maltodextrin) or a 1 x 109CFU dose of Veillonella atypica FB004 (VA) (Fitbiomics, Inc. New York). After supplementing for 14 days, participants will complete an identical battery of tests. Participants will then follow a wash-out period for 21 days before returning to the laboratory to complete study visit 5, the pre-supplementation visit to their supplementation period. After completing study visit 5, participants will be instructed to supplement with the alternative supplement for 14 days before returning for a 6th and final study visit. Participants will complete a two-day food and fluid record prior to visit 3, receivea copy of it from study investigators, and be instructed to replicate it prior to each subsequent study visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05816291
Study type Interventional
Source Lindenwood University
Contact
Status Completed
Phase N/A
Start date March 30, 2022
Completion date July 26, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05108467 - Saving Lives by Early Detection and Treatment of Sepsis and Septic Shock by Point of Care Lactate Test in Adults
Completed NCT04641104 - The Thiamine Administration After Cardiac Surgery Trial Phase 4
Not yet recruiting NCT03115970 - Feasibility of Lactate Level Evaluation in Prehospital Care in Trauma N/A
Recruiting NCT03831685 - Blood Lactate Level for Pre-hospital Orientation of Septic Shock
Completed NCT03974906 - Goal-directed Fluid Therapy in Elderly Patients Undergoing Lumbar Surgery N/A
Not yet recruiting NCT03980678 - Lithothamnion Species on Blood Lactate During Exhaustive Exercise in Trained Cyclists N/A
Completed NCT04777747 - The Role of Lactate in Viral and Bacterial Infection
Completed NCT05611398 - Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention
Recruiting NCT03062683 - Serum Lactate in Convulsive Syncopes Compared to Non-convulsive Syncopes N/A
Completed NCT05295836 - Effects of Acute Glycerol Ingestion on Performance, Metabolic and Biochemical Markers in International Athletes N/A
Completed NCT06292910 - Central Venous to Arterial CO2 Difference and Low Cardiac Output Syndrome Related Outcomes in Children After Cardiac Surgery
Active, not recruiting NCT04796285 - A Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor N/A